Polycystic Ovary Syndrome (PCOS)
Polycystic ovary syndrome is one of the most common endocrine disorders affecting people with ovaries, with the National Institutes of Health estimating that between 6% and 12% of reproductive-age women in the United States meet diagnostic criteria. The condition involves disrupted hormone signaling, impaired ovarian function, and metabolic consequences that extend well beyond fertility concerns. This page covers the clinical definition, underlying mechanisms, presenting scenarios, and the diagnostic boundaries that distinguish PCOS from overlapping conditions — all framed within established clinical and regulatory guidance. For broader context on how hormonal conditions are evaluated and governed, the regulatory context for endocrinology provides relevant institutional background.
Definition and scope
PCOS is defined by the presence of at least 2 of 3 criteria established by the 2003 Rotterdam Consensus, which was developed by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM). These criteria are:
- Oligo-ovulation or anovulation — infrequent or absent ovulation, typically presenting as irregular or absent menstrual cycles
- Clinical or biochemical hyperandrogenism — elevated androgens confirmed by blood testing, or physical signs such as hirsutism, acne, or androgenic alopecia
- Polycystic ovarian morphology — 12 or more follicles (by older ultrasound standards) or increased ovarian volume on pelvic ultrasound, though the 2018 international evidence-based guideline from ESHRE/ASRM updated the follicle threshold to 20 or more per ovary on modern high-frequency ultrasound equipment
The scope of PCOS extends beyond reproduction. The condition carries elevated risk for type 2 diabetes, cardiovascular risk factors, non-alcoholic fatty liver disease, and obstructive sleep apnea. The Endocrine Society's 2023 clinical practice guideline on PCOS identifies insulin resistance as a central metabolic feature present in approximately 65% to 70% of affected individuals, regardless of body weight.
How it works
The pathophysiology of PCOS involves dysregulation at multiple points in the hypothalamic-pituitary-ovarian axis. In a normal cycle, the pituitary gland releases luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in a pulsatile, tightly regulated ratio. In PCOS, LH pulse frequency and amplitude are elevated relative to FSH, which preferentially stimulates ovarian theca cells to overproduce androgens — primarily testosterone and androstenedione.
This androgen excess disrupts follicular maturation. Follicles begin development but arrest at an intermediate stage, producing the characteristic "string of pearls" appearance on ultrasound. The elevated androgen environment also suppresses the midcycle LH surge required for ovulation, creating a self-reinforcing cycle of anovulation.
Insulin resistance compounds the process. Elevated circulating insulin stimulates theca cells directly and suppresses hepatic production of sex hormone-binding globulin (SHBG), increasing free androgen availability. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) classifies insulin resistance in PCOS as a distinct pathway that, if unaddressed, significantly raises the probability of progression to type 2 diabetes over a 10-year horizon.
Genetic factors also contribute. First-degree relatives of individuals with PCOS show higher rates of hyperandrogenism and metabolic syndrome, though no single causative gene has been identified.
Common scenarios
PCOS presents differently depending on the predominant hormonal phenotype and the patient's metabolic status. Four recognized clinical phenotypes (A through D) were codified following the Rotterdam criteria and differ by which diagnostic elements are present:
| Phenotype | Anovulation | Hyperandrogenism | Polycystic Morphology |
|---|---|---|---|
| A (classic) | ✓ | ✓ | ✓ |
| B (classic) | ✓ | ✓ | — |
| C (ovulatory) | — | ✓ | ✓ |
| D (non-androgenic) | ✓ | — | ✓ |
Phenotype A carries the highest metabolic risk. Phenotype D, by contrast, carries lower androgen burden but remains a recognized diagnostic category under Rotterdam criteria.
Three common clinical presentations illustrate the range:
- Adolescent presentation: Irregular cycles within 2 years of menarche are normal, so diagnosis in adolescents requires both hyperandrogenism and irregular cycles persisting beyond 2 years post-menarche, without relying on ultrasound morphology (per the 2018 ESHRE international guideline).
- Reproductive-age presentation with infertility: Anovulatory infertility is the most frequent reason for PCOS-related specialist referral. Patients seeking fertility and hormonal imbalance evaluation typically require documentation of ovulatory status alongside androgen panels.
- Metabolic-predominant presentation: Patients with obesity, acanthosis nigricans, and impaired fasting glucose may present with metabolic features before irregular cycles prompt investigation. In this scenario, PCOS must be distinguished from insulin resistance of other causes through systematic exclusion.
Decision boundaries
Distinguishing PCOS from conditions that mimic it is a mandatory step before diagnosis. The Endocrine Society guideline specifies that thyroid dysfunction, hyperprolactinemia, non-classic congenital adrenal hyperplasia (NCCAH), androgen-secreting tumors, and Cushing syndrome must all be formally excluded.
Key exclusion tests include:
- TSH — to rule out hypothyroidism, which can cause anovulation independently
- Prolactin — hyperprolactinemia produces similar cycle disruption via pituitary pathways
- 17-hydroxyprogesterone (17-OHP) — NCCAH due to 21-hydroxylase deficiency can present identically to PCOS; a morning follicular-phase 17-OHP above 2 ng/mL warrants ACTH stimulation testing
- 24-hour urine free cortisol or late-night salivary cortisol — when Cushing syndrome features are present, such as central obesity, striae, or hypertension in combination
The distinction between PCOS and functional hypothalamic amenorrhea (FHA) is particularly important because treatment directions diverge substantially. FHA is characterized by low LH, low estradiol, and suppressed gonadotropin-releasing hormone (GnRH) pulsatility — often in the context of energy deficit or excessive exercise — whereas PCOS typically shows elevated LH with normal or elevated estrogen.
Once PCOS is confirmed, metabolic risk stratification is required. The Endocrine Society recommends screening for impaired glucose tolerance using a 2-hour 75-gram oral glucose tolerance test rather than fasting glucose alone, because fasting values underdetect dysglycemia in this population. Lipid panels, blood pressure measurement, and depression screening are also incorporated into comprehensive PCOS evaluation.
Endocrinology and gynecology specialists co-manage PCOS when metabolic and reproductive concerns overlap — a clinical scenario discussed in the broader context of endocrine conditions across the endocrinology authority index.
References
- National Institutes of Health — PCOS Overview (NICHD)
- Endocrine Society — PCOS Clinical Practice Guideline (2023)
- ESHRE/ASRM — International Evidence-Based Guideline for PCOS (2018)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — Insulin Resistance and Prediabetes
- American Society for Reproductive Medicine (ASRM)
The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)